Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 4, 2004, Pages 445-449

  Svejgaard, El ^a,b   Larsen, P Ølholm ^a,c   Deleuran, M ^a,d   Ternowitz, T ^a,e   Roed Petersen, J ^a,f   Nilsson, J ^a,g  

^a Mental Health Services CPH   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Department of Dermatology ^*  (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g Department of Dermatology   (Denmark)

Author keywords

Atopic dermatitis; Itraconazole; SCORAD

Indexed keywords

FUNGUS ANTIGEN; ITRACONAZOLE; PLACEBO;

ADULT; ARTICLE; ATOPIC DERMATITIS; CANDIDA ALBICANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEAD AND NECK INFECTION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALASSEZIA; MALE; PITYROSPORUM OVALE; PREGNANCY TEST; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; ECZEMA; FACIAL DERMATOSES; FEMALE; HUMANS; HYPERSENSITIVITY; ITRACONAZOLE; MALASSEZIA; MALE; NECK; SKIN TESTS;

EID: 3242766978     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00963.x     Document Type: Article

References (14)

1. Nakabayshi A, Su Y, Guillot J. Identification of Malassezia species isolated from patients with seboroic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000; 38: 337-341.
2. Kieffer M, Bergbrant I-M, Faergemann J, Jemec GBE, Ottevanger V, Skov PS, Svejgaard E. Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrhoeic dermatitis. J Am Acad Dermatol 1990; 22: 739-742.
3. Rokugo M, Tagami H, Usuba Y, Tomita Y. Contact sensitivity to Pityrosporum ovale in patients with an atopic dermatitis. Arch Dermatol 1990; 126: 627-634.
4. Wessels MW, Doekes G, Van Ieperen-Van Oijk AG, Koers WJ, Young E IgE. antibodies to Pityrosporum ovale in atopic dermatitis. Br J Dermatol 1991; 125: 227-232.
5. Kim TY, Jang IG, Park YM, Kim HO, Kim CW. Head and neck dermatitis: the role of Malassezia furfur, topical steroid use and environmental factors in its causation. Clin Exp Dermatol 1999; 24: 226-231.
6. Bäck O, Scheynius A, Johansson SGO. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995; 287: 448-451.
7. Broberg A, Fæxrgemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area: a double-blind randomised study. Acta Derm Venereol (Stockh) 1995; 75: 46-49.
8. Clemmensen OJ, Hjorth N. Treatment of dermatitis of the head and neck with ketoconazole in patients with Type I sensitivity to Pityrosporum orbiculare. Semin Dermatol 1983; 2: 26-29.
9. Hiruma S et al. Treatment of face lesions in adult atopic dermatitis with itraconazole. Jpn J Med Mycol 1995; 36 (Suppl. 1): 74.
10. Kolmer HL, Platts-Mills TAE. Atopic dermatitis: new knowledge and new approaches. Hosp Pract 1995; 30: 67-72.
11. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl 1980; 92: 44-47.
12. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 23-31.
13. Cauwenberg G, Degreef H, Heykants J et al. Pharmacokinetic profile of orally administered itraconazole in the human skin. J Am Acad Dermatol 1988; 18: 263-268.
14. Delescluse J. Itraconazole in tinea versicolor: a review. J Am Acad Dermatol 1990; 23: 551-554.